Dihydroorotate dehydrogenase
- India
Rhizen Pharmaceuticals Announces US FDA Acceptance of its IND Application for RP7214 in SARS-CoV-2 Infection; Phase 1 Clinical Trial of RP7214 Set to Begin Early December 2020
LA CHAUX DU FONDS, Switzerland: Rhizen announces the approval of its IND by USFDA for its oral DHODH inhibitor for…
Read More »